Overcoming tumor immune evasion involves blocking inhibitory receptors (e.g., TIGIT, PD-1, and NKG2A) and targeting suppressive tumor metabolites to enhance NK activation [182]. The gene discussed is KLRC1; the disease is neoplasm.